Australien - engelsk - Department of Health (Therapeutic Goods Administration)

ms health pty ltd - 47017 - syringe, general-purpose - suction syringe for the evacuation of waste products from the uterus.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

ms health pty ltd - 32655 - cannula, uterine, suction - suction catheter for evacuation of waste products from the uterus.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - morphine sulfate -

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

ms health pty ltd - mifepristone -

Australien - engelsk - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ccd animal health pty ltd - oxytetracycline hydrochloride - oral powder, pre-mix - oxytetracycline hydrochloride antibiotic active 100.0 g/kg - parasiticides - calf | honey bees | pigs | poultry | sheep | beef calf | boar | bovine | breeders | broiler | calf - poddy | calf - preweaning | - bacterial calf scours | bacterial enteritis | chronic respiratory disease complex | colibacillosis | coryza | dermatitis | diptheria | european brood disease | infectious sinusitis | infectious synovitis | leptospirosis | mycoplasma hyopneumoniae | necrotic enteritis | oedema | pasteurella multocida | pasteurella spp. | pneumonia | salmonella | bacterial pneumonia | discharging sinuses | european foulbrood | fowl cholera | gangrenous | including b-lactamase producin | infectious coryza | l. hardjo | l. interrogans | l. pomona | l. tarassovi | ms | pasterellosis | pasteurellosis | physiological of the mammary g | post-weaning bacterial enterit | reduction of lung lesions | respiratory disease | salmonellosis | skin disorder | swine enzootic pneumonia

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - interferon beta-1a, quantity: 88 microgram/ml - injection, solution - excipient ingredients: methionine; acetic acid; mannitol; poloxamer; water for injections; benzyl alcohol; sodium hydroxide - rebif is indicated for the treatment of: ? patients with a single demyelinating event in the central nervous system with an active inflammatory process, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis. high risk can be inferred from cerebral mri with 2 or more lesions suggestive of demyelination.,? ambulatory patients with multiple sclerosis who have experienced two or more relapses within the last 2 years. rebif therapy should not be initiated in secondary progressive ms patients who no longer experience relapses.?

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - interferon beta-1a, quantity: 88 microgram/ml - injection, solution - excipient ingredients: benzyl alcohol; water for injections; sodium hydroxide; acetic acid; methionine; poloxamer; mannitol - rebif is indicated for the treatment of: ? patients with a single demyelinating event in the central nervous system with an active inflammatory process, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis. high risk can be inferred from cerebral mri with 2 or more lesions suggestive of demyelination.,? ambulatory patients with multiple sclerosis who have experienced two or more relapses within the last 2 years. rebif therapy should not be initiated in secondary progressive ms patients who no longer experience relapses.?

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - interferon beta-1a, quantity: 88 microgram/ml - injection, solution - excipient ingredients: benzyl alcohol; water for injections; sodium hydroxide; acetic acid; methionine; poloxamer; mannitol - rebif is indicated for the treatment of: ? patients with a single demyelinating event in the central nervous system with an active inflammatory process, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis. high risk can be inferred from cerebral mri with 2 or more lesions suggestive of demyelination.,? ambulatory patients with multiple sclerosis who have experienced two or more relapses within the last 2 years. rebif therapy should not be initiated in secondary progressive ms patients who no longer experience relapses.?

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - morphine sulfate pentahydrate -

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - morphine sulfate pentahydrate -